Join Andelyn’s Newsletter

Your Source for Quality Insights on Cell and Gene Therapies

We are committed to advancing the future of cell and gene therapies. By subscribing to our newsletter, you’ll receive:

Expert perspectives on the latest industry developments

Educational content on therapies from concept to commercialization

Exclusive insights into our pioneering work in rare diseases

Updates on conference attendance and technical presentations

News & Press Releases

Press Release

October 9, 2024

Andelyn Biosciences Selected by Hubble Therapeutics to Manufacture Clinical Grade AAV for the Treatment of Leber Congenital Amaurosis (LCA16) Andelyn Biosciences Selected by Hubble Therapeutics to Manufacture Clinical Grade AAV for the Treatment of Leber Congenital Amaurosis (LCA16)

Press Release

August 6, 2024

Andelyn Biosciences Expands AAV Curator™ Platform Offering to Include MyoAAV Plasmids through a License Agreement from the Broad Institute of MIT and Harvard Andelyn Biosciences Expands AAV Curator™ Platform Offering to Include MyoAAV Plasmids through a License Agreement from the Broad Institute of MIT and Harvard

Press Release

July 10, 2024

Andelyn Biosciences Selected by UMass Chan Medical School to Manufacture Clinical Grade AAV9-CSA Vector to Treat Cockayne Syndrome Andelyn Biosciences Selected by UMass Chan Medical School to Manufacture Clinical Grade AAV9-CSA Vector to Treat Cockayne Syndrome

News

June 11, 2024

UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome

View All News & Press Releases

By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Preferences Deny Accept